Yan-Ming Ren1, Xia Wu2, Chao You1, Yue-Kang Zhang1, Qiang Li1, Yan Ju3. 1. Department of Neurosurgery, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, People's Republic of China. 2. Department of Pathology, West China Second Hospital of Sichuan University, Chengdu, Sichuan Province, People's Republic of China. 3. Department of Neurosurgery, West China Hospital of Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan Province, People's Republic of China. juyanwestchina@126.com.
Abstract
OBJECTIVES: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare, highly malignant tumor of the central nervous system with poor prognosis. Nowadays, multimodal management, including surgery, chemotherapy (CMT), and radiation therapy (RT), is advocated. However, AT/RT treatment with gamma knife surgery (GKS) was rarely reported. The aim of this study was to assess the efficacy and safety of GKS for the treatment of AT/RT. PATIENTS AND METHODS: Medical records of AT/RT patients who underwent surgery from 2007 to 2014 at the West China Hospital were retrospectively reviewed and statistically analyzed. RESULTS: Eighteen patients (12 males and 6 females) were presented with AT/RTs. Median age during presentation was 20.5 months (range, 4-179 months). Twelve patients were < 3 years and six patients were > 3 years. Tumor location was supratentorial in seven patients, infratentorial in ten patients, and center area of the brain in one patient. Treatments performed were as follows: surgery alone in two patients, surgery+RT in two patients, surgery+CMT in five patients, surgery+CMT+RT in two patients, and surgery+CMT+RT+GKS in seven patients. The 2-year overall survival (OS) rate and event-free survival (EFS) rate for all 18 consecutive patients were 33.3 and 27.8%, respectively. Cox regression analyses showed that multimodal management combined with GKS was an independent positive prognostic factor for OS. CONCLUSIONS: Although AT/RTs are lethal cancer types, the OS of the disease was improved by using multimodal therapeutic strategies, including surgery, CMT, and RT, combined with GKS.
OBJECTIVES: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare, highly malignant tumor of the central nervous system with poor prognosis. Nowadays, multimodal management, including surgery, chemotherapy (CMT), and radiation therapy (RT), is advocated. However, AT/RT treatment with gamma knife surgery (GKS) was rarely reported. The aim of this study was to assess the efficacy and safety of GKS for the treatment of AT/RT. PATIENTS AND METHODS: Medical records of AT/RT patients who underwent surgery from 2007 to 2014 at the West China Hospital were retrospectively reviewed and statistically analyzed. RESULTS: Eighteen patients (12 males and 6 females) were presented with AT/RTs. Median age during presentation was 20.5 months (range, 4-179 months). Twelve patients were < 3 years and six patients were > 3 years. Tumor location was supratentorial in seven patients, infratentorial in ten patients, and center area of the brain in one patient. Treatments performed were as follows: surgery alone in two patients, surgery+RT in two patients, surgery+CMT in five patients, surgery+CMT+RT in two patients, and surgery+CMT+RT+GKS in seven patients. The 2-year overall survival (OS) rate and event-free survival (EFS) rate for all 18 consecutive patients were 33.3 and 27.8%, respectively. Cox regression analyses showed that multimodal management combined with GKS was an independent positive prognostic factor for OS. CONCLUSIONS: Although AT/RTs are lethal cancer types, the OS of the disease was improved by using multimodal therapeutic strategies, including surgery, CMT, and RT, combined with GKS.
Authors: Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi Journal: Neuro Oncol Date: 2016-01-10 Impact factor: 12.300
Authors: Jack Raisanen; Jaclyn A Biegel; Kimmo J Hatanpaa; Alexander Judkins; Charles L White; Arie Perry Journal: Brain Pathol Date: 2005-01 Impact factor: 6.508
Authors: Jaclyn A Biegel; Lu Tan; Fan Zhang; Luanne Wainwright; Pierre Russo; Lucy B Rorke Journal: Clin Cancer Res Date: 2002-11 Impact factor: 12.531
Authors: L Lafay-Cousin; C Hawkins; A S Carret; D Johnston; S Zelcer; B Wilson; N Jabado; K Scheinemann; D Eisenstat; C Fryer; A Fleming; C Mpofu; V Larouche; D Strother; E Bouffet; A Huang Journal: Eur J Cancer Date: 2011-10-22 Impact factor: 9.162
Authors: Quinn T Ostrom; Peter M de Blank; Carol Kruchko; Claire M Petersen; Peter Liao; Jonathan L Finlay; Duncan S Stearns; Johannes E Wolff; Yingli Wolinsky; John J Letterio; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2015-01 Impact factor: 12.300
Authors: Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Winona W Wu; Wenya Linda Bi; Yun Jee Kang; Shakti H Ramkissoon; Sashank Prasad; Helen A Shih; David A Reardon; Ian F Dunn Journal: World Neurosurg Date: 2015-09-04 Impact factor: 2.104
Authors: Alexandra Richards; Ronak Ved; Christopher Murphy; Dawn Hennigan; John-Paul Kilday; Ian Kamaly-Asl; Conor Mallucci; Imran Bhatti; Chirag Patel; Paul Leach Journal: Childs Nerv Syst Date: 2019-12-31 Impact factor: 1.475